Liposomal Bupivacaine Infiltration vs Continuous Perineural Ropivacaine Infusion for Post-operative Pain After Total Shoulder Arthroplasty
Bupivacaine 1.3% Liposomal Suspension (Exparel) vs Continuous Perineural Ropivacaine Infusion in the Management of Post-operative Pain Following Total Shoulder Arthroplasty; An Open-label, Randomized, Controlled Study
Sponsor: Eric Shepard
Terminated
Low enrollment
A PHASE4 clinical study on Postoperative Pain and Shoulder Arthritis, this trial is terminated or withdrawn. The trial is conducted by Eric Shepard and has accumulated 8 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Sep 2019 — Jan 2021 [monthly]
Terminated PHASE4
-
Jun 2018 — Sep 2019 [monthly]
Terminated PHASE4
▶ Show 3 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Terminated PHASE4
Status: Active Not Recruiting → Terminated
-
Feb 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Aug 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eric Shepard
- Pacira Pharmaceuticals, Inc
For direct contact, visit the study record on ClinicalTrials.gov .